Delivery Order SPE2DB20D7066-SPE2DB25FC4NZ
- Not listed
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Rocuronium 100 mg/10 ml vials with a ceiling value of $1,105.56. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competitively awarded through open procurement...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Rocuronium 100 mg/10 mL vials with a ceiling value of $1,166.98 and a firm fixed price structure. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of August 14, 2025, and performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for Rocuronium 100 mg/10 mL vials valued at $1,105.56 on July 18, 2025, with completion scheduled for July 21, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child order under a larger contract vehicle supporting federal...
- This delivery order, awarded on July 23, 2025, by the Defense Logistics Agency (DLA) Medical Supply Chain to AmerisourceBergen Drug Corp, provides Rocuronium 100 mg/10 ml vials totaling $1,105.56 under firm fixed pricing with delivery required by July 24, 2025. The award represents a competitive, non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through December 2026....
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Rocuronium 100 mg/10 mL vials. This competitively awarded, non-set-aside contract carries a ceiling value of $1,105.56 and is scheduled for completion by August 5, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and holds an...
- This federal contract award, valued at $1,105.56, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order (SPE2DX15D2223|SPE2DX25F4JPG) for the supply of 100 mg/10 mL vials of the drug Rocuronium, a muscle relaxant used in anesthesia. The contract has an ultimate completion date of May 1, 2025 and is a firm fixed-price arrangement. It is not designated as a set-aside...
- The Defense Logistics Agency Troop Support Medical awarded a $21,550 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 50 mg/5 mL vials of rocuronium bromide. The single order is for procurement of this neuromuscular blocking agent to be delivered to a Conshohocken, Pennsylvania facility between July 25-26, 2023. Amerisourcebergen will perform as the prime contractor, with no indication of involvement by major subcontractors. The Defense Logistics Agency manages the...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, provides for the delivery of Rocuronium 50 mg/5 ml vials. The $1,374.24 firm-fixed-price delivery order was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the U.S. Department of Defense. The award is associated with a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued at $999,999,999 and running through November 2026. This IDC...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the delivery of 4,565,377,731 units of the drug Rocuronium 100 mg/10 ml vial (10 ml). The firm-fixed-price delivery order, valued at $1,128.03, has an ultimate completion date of August 8, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the drug Rocuronium 50 mg/5 ml vial. The contract has a firm fixed price of $2,308.95 and a completion date of June 17, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive global...
- SPE2DB20D7066Indefinite Delivery Contract
- SPE2DB20D7066-SPE2DB25FC4NZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,228.60 to AmerisourceBergen Drug Corp for Rocuronium 100 mg/10 ml vials on September 2, 2025, with completion scheduled for September 3, 2025. This firm fixed-price delivery order was competitively awarded without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Rocuronium is a neuromuscular blocking agent commonly used in anesthesia and critical care settings, making this procurement consistent with the Defense Health Agency's medical supply requirements. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), a $999.9 billion prime vendor agreement running through December 2026 that provides comprehensive pharmaceutical support to military healthcare programs globally. As a leading pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp maintains an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's qualification as a prime vendor through this large-scale IDC demonstrates its capability to meet stringent federal procurement standards and support the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/2/25 |